...

A study to test how well an injectable treatment combination (CAB LA + RPV LA) works for people with HIV-1 who still have detectable levels of the virus (CROWN study)

This study will evaluate how well, how safe, and how long-lasting a treatment called CAB LA + RPV LA is for people with HIV who still have detectable virus levels even though they are taking oral ART. The study will also consider feedback from patients on their experience with this treatment.


Why this Research Matters

The CROWN study is evaluating a potential injectable HIV treatment option (the "study drug") for people whose HIV is not undetectable. If eligible, you will be assigned by chance to a study treatment group. You will have a 3-in-4 chance of being in Group 1 and a 1-in-4 chance of being in Group 2. Group 1 will have study drug injections once every 2 months after 2 once-monthly starter doses. Group 2 will take oral ART for 6 months followed by study drug injections once every 2 months after 2 once-monthly starter doses.


Who can Participate

Adult

You may be eligible to participate in the CROWN study if you are: -18 years of age or older -Living with HIV that is not undetectable -Currently being treated with oral antiretroviral therapy (ART)


Study ID

Protocol Number: 24-1607
More information available at ClinicalTrials.gov: NCT06694805

Meet the Team

Image of Principal Investigator

Thomas Campbell, MD

Principal Investigator